ARROWHEAD PHARMACEUTICALS IN (ARWR) Fundamental Analysis & Valuation

NASDAQ:ARWR • US04280A1007

Current stock price

56.33 USD
-0.63 (-1.11%)
At close:
57.1826 USD
+0.85 (+1.51%)
After Hours:

This ARWR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ARWR Profitability Analysis

1.1 Basic Checks

  • In the past year ARWR was profitable.
  • ARWR had a positive operating cash flow in the past year.
  • ARWR had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ARWR reported negative operating cash flow in multiple years.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 12.61%, ARWR belongs to the top of the industry, outperforming 94.58% of the companies in the same industry.
  • With an excellent Return On Equity value of 35.58%, ARWR belongs to the best of the industry, outperforming 97.49% of the companies in the same industry.
  • ARWR has a Return On Invested Capital of 13.98%. This is amongst the best in the industry. ARWR outperforms 95.94% of its industry peers.
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROIC 13.98%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • The Profit Margin of ARWR (18.54%) is better than 93.04% of its industry peers.
  • ARWR's Operating Margin of 27.55% is amongst the best of the industry. ARWR outperforms 95.55% of its industry peers.
Industry RankSector Rank
OM 27.55%
PM (TTM) 18.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ARWR Health Analysis

2.1 Basic Checks

  • ARWR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, ARWR has more shares outstanding
  • ARWR has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ARWR has been reduced compared to a year ago.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ARWR has an Altman-Z score of 5.14. This indicates that ARWR is financially healthy and has little risk of bankruptcy at the moment.
  • ARWR has a better Altman-Z score (5.14) than 74.08% of its industry peers.
  • ARWR has a debt to FCF ratio of 1.80. This is a very positive value and a sign of high solvency as it would only need 1.80 years to pay back of all of its debts.
  • ARWR's Debt to FCF ratio of 1.80 is amongst the best of the industry. ARWR outperforms 93.81% of its industry peers.
  • A Debt/Equity ratio of 0.95 indicates that ARWR is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ARWR (0.95) is worse than 74.47% of its industry peers.
  • Although ARWR's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Altman-Z 5.14
ROIC/WACC1.71
WACC8.19%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • ARWR has a Current Ratio of 3.38. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ARWR (3.38) is worse than 60.15% of its industry peers.
  • ARWR has a Quick Ratio of 3.38. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
  • ARWR has a Quick ratio of 3.38. This is comparable to the rest of the industry: ARWR outperforms 41.97% of its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ARWR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 129.65% over the past year.
  • ARWR shows a strong growth in Revenue. In the last year, the Revenue has grown by 43539.24%.
  • The Revenue has been growing by 56.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%

3.2 Future

  • Based on estimates for the next years, ARWR will show a very strong growth in Earnings Per Share. The EPS will grow by 101.11% on average per year.
  • ARWR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y-4212.69%
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%
EPS Next 5Y101.11%
Revenue Next Year-40.29%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. ARWR Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 36.82, ARWR can be considered very expensive at the moment.
  • 91.49% of the companies in the same industry are more expensive than ARWR, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 25.23. ARWR is valued slightly more expensive when compared to this.
  • ARWR is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 36.82
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ARWR is valued cheaper than 93.23% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ARWR is valued cheaply inside the industry as 94.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 24.5
EV/EBITDA 21.26
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • ARWR's earnings are expected to decrease with -236.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARWR Dividend Analysis

5.1 Amount

  • ARWR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARWR Fundamentals: All Metrics, Ratios and Statistics

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (3/20/2026, 8:00:01 PM)

After market: 57.1826 +0.85 (+1.51%)

56.33

-0.63 (-1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05
Earnings (Next)05-11
Inst Owners84.19%
Inst Owner Change3.88%
Ins Owners3.67%
Ins Owner Change-0.46%
Market Cap7.89B
Revenue(TTM)1.09B
Net Income(TTM)202.26M
Analysts80
Price Target81.43 (44.56%)
Short Float %8.27%
Short Ratio3.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.98%
Min EPS beat(2)-14.75%
Max EPS beat(2)26.7%
EPS beat(4)2
Avg EPS beat(4)363.28%
Min EPS beat(4)-20.51%
Max EPS beat(4)1461.66%
EPS beat(8)2
Avg EPS beat(8)69.08%
EPS beat(12)3
Avg EPS beat(12)46.94%
EPS beat(16)4
Avg EPS beat(16)35.01%
Revenue beat(2)1
Avg Revenue beat(2)19.41%
Min Revenue beat(2)-4.15%
Max Revenue beat(2)42.98%
Revenue beat(4)3
Avg Revenue beat(4)433.43%
Min Revenue beat(4)-4.15%
Max Revenue beat(4)1680.09%
Revenue beat(8)3
Avg Revenue beat(8)167.14%
Revenue beat(12)4
Avg Revenue beat(12)110.57%
Revenue beat(16)5
Avg Revenue beat(16)76.26%
PT rev (1m)-0.59%
PT rev (3m)37.46%
EPS NQ rev (1m)-1.72%
EPS NQ rev (3m)-6.8%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)-4.94%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)5.31%
Revenue NY rev (1m)13.22%
Revenue NY rev (3m)16.82%
Valuation
Industry RankSector Rank
PE 36.82
Fwd PE N/A
P/S 7.23
P/FCF 24.5
P/OCF 23.25
P/B 13.88
P/tB 14.04
EV/EBITDA 21.26
EPS(TTM)1.53
EY2.72%
EPS(NY)-4.29
Fwd EYN/A
FCF(TTM)2.3
FCFY4.08%
OCF(TTM)2.42
OCFY4.3%
SpS7.79
BVpS4.06
TBVpS4.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.82
Profitability
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROCE 23.92%
ROIC 13.98%
ROICexc 51.35%
ROICexgc 52.33%
OM 27.55%
PM (TTM) 18.54%
GM N/A
FCFM 29.52%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Debt/EBITDA 1.65
Cap/Depr 68.96%
Cap/Sales 1.59%
Interest Coverage 250
Cash Conversion 104.19%
Profit Quality 159.2%
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 5.14
F-Score7
WACC8.19%
ROIC/WACC1.71
Cap/Depr(3y)756.37%
Cap/Depr(5y)612.23%
Cap/Sales(3y)1353.35%
Cap/Sales(5y)819.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
EPS Next Y-4212.69%
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%
EPS Next 5Y101.11%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%
Revenue Next Year-40.29%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%
EBIT growth 1Y148.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-477.94%
EBIT Next 3Y-105.85%
EBIT Next 5Y49.99%
FCF growth 1Y179.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y272.91%
OCF growth 3YN/A
OCF growth 5YN/A

ARROWHEAD PHARMACEUTICALS IN / ARWR Fundamental Analysis FAQ

What is the fundamental rating for ARWR stock?

ChartMill assigns a fundamental rating of 5 / 10 to ARWR.


What is the valuation status of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

ChartMill assigns a valuation rating of 3 / 10 to ARROWHEAD PHARMACEUTICALS IN (ARWR). This can be considered as Overvalued.


What is the profitability of ARWR stock?

ARROWHEAD PHARMACEUTICALS IN (ARWR) has a profitability rating of 5 / 10.


How financially healthy is ARROWHEAD PHARMACEUTICALS IN?

The financial health rating of ARROWHEAD PHARMACEUTICALS IN (ARWR) is 7 / 10.


Can you provide the expected EPS growth for ARWR stock?

The Earnings per Share (EPS) of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to decline by -4212.69% in the next year.